Literature DB >> 16766394

Serum levels of interleukin 1beta, interleukin 8 and tumour necrosis factor alpha as markers of gastric cancer.

A Macrì1, A Versaci, S Loddo, G Scuderi, M Travagliante, G Trimarchi, D Teti, C Famulari.   

Abstract

Despite the efforts made, a serum marker reliable for the screening and follow-up of patients with gastric cancer has not yet been identified. The aim of this preliminary study was to test the role of pro-inflammatory cytokines interleukin 1beta, interleukin 8 and tumour necrosis factor alpha in patients with gastric cancer and in control groups. The statistical analysis of cytokines serum levels in the group with gastric cancer versus control groups has shown considerable differences (p < 0.001) in their mean rates. The results indicate that the cytokines interleukin 1beta, interleukin 8 and tumour necrosis factor alpha might perhaps act as diagnostic markers in patients with gastric cancer. Therefore, it is hypothesized that after more extended trials, their use in the screening and prognostic assessment of these patients could be a possibility.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16766394     DOI: 10.1080/13547500600565677

Source DB:  PubMed          Journal:  Biomarkers        ISSN: 1354-750X            Impact factor:   2.658


  22 in total

Review 1.  The contrasting roles of inflammasomes in cancer.

Authors:  Qin He; Yu Fu; Dean Tian; Wei Yan
Journal:  Am J Cancer Res       Date:  2018-04-01       Impact factor: 6.166

2.  Correlation of Helicobacter pylori and interleukin-8 mRNA expression in high risk gastric cancer population prediction.

Authors:  Wilaiwan Chongruksut; Sirikan Limpakan Yamada; Bandhuphat Chakrabandhu; Chidchanok Ruengorn; Sirisak Nanta
Journal:  World J Gastrointest Oncol       Date:  2016-02-15

3.  Circulating cytokines and gastric cancer risk.

Authors:  Meira Epplein; Yong-Bing Xiang; Qiuyin Cai; Richard M Peek; Honglan Li; Pelayo Correa; Jing Gao; Jie Wu; Angelika Michel; Michael Pawlita; Wei Zheng; Xiao-Ou Shu
Journal:  Cancer Causes Control       Date:  2013-09-20       Impact factor: 2.506

Review 4.  Role of the tumor microenvironment in the pathogenesis of gastric carcinoma.

Authors:  Hye Won Chung; Jong-Baeck Lim
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

Review 5.  CXC chemokines and chemokine receptors in gastric cancer: from basic findings towards therapeutic targeting.

Authors:  Hyo Jin Lee; Ik-Chan Song; Hwan-Jung Yun; Deog-Yeon Jo; Samyong Kim
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

6.  CD38 expression as response of hematopoietic system to cancer.

Authors:  Işil Albeniz; Ozlem Demir-Coşkun; Leyla Türker-Şener; Aycan Baş; Oktar Asoğlu; Rüstem Nurten
Journal:  Oncol Lett       Date:  2011-05-16       Impact factor: 2.967

Review 7.  Helicobacter pylori and interleukin-8 in gastric cancer.

Authors:  Ko Eun Lee; Pham Ngoc Khoi; Yong Xia; Jung Sun Park; Young Eun Joo; Kyung Keun Kim; Seok Yong Choi; Young Do Jung
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

8.  Cross-talk between LPA1 and epidermal growth factor receptors mediates up-regulation of sphingosine kinase 1 to promote gastric cancer cell motility and invasion.

Authors:  Dai Shida; Xianjun Fang; Tomasz Kordula; Kazuaki Takabe; Sandrine Lépine; Sergio E Alvarez; Sheldon Milstien; Sarah Spiegel
Journal:  Cancer Res       Date:  2008-08-15       Impact factor: 12.701

9.  Clinical significance of serum interleukin-29, interleukin-32, and tumor necrosis factor alpha levels in patients with gastric cancer.

Authors:  Kayhan Erturk; Didem Tastekin; Murat Serilmez; Elif Bilgin; Hamza Ugur Bozbey; Sezai Vatansever
Journal:  Tumour Biol       Date:  2015-07-29

10.  Serum C-reactive protein (CRP) levels in cancer patients are linked with tumor burden and are reduced by anti-hypertensive medication.

Authors:  Michael I Koukourakis; Georgia Kambouromiti; Dimitra Pitsiava; Pelagia Tsousou; Maria Tsiarkatsi; George Kartalis
Journal:  Inflammation       Date:  2009-06       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.